Hospital

Research presented at the American Association for Cancer Research Annual Meeting shows personalized mRNA vaccine immunotherapy targets pancreatic cancer tumor neoantigens, sparking durable T-cell responses and boosting survival in a phase 1 clinical trial.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.

There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

Experts describe how infectious disease pharmacists drive antimicrobial stewardship, tackle resistance, and shape global training as SIDP marks 35 years.

Adjuvant PD-1/PD-L1 inhibitors improve disease-free and metastasis-free survival in patients with solid tumors but require careful patient selection.

When performed appropriately, medication reconciliations can reduce discrepancies from as high as 70% to as low as 15%.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices such as cemiplimab, and access tips for treating non–small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

This decision builds upon the drug’s initial approval for adult patients and introduces a new therapeutic option for clinicians treating pediatric populations with rapid heart rate disturbances.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.